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ABSTRACT
Background Neurodevelopmental disorders have
challenged clinical genetics for decades, with over 700
genes implicated and many whose function remains
unknown. The application of whole-exome sequencing is
proving pivotal in closing the genotype/phenotype gap
through the discovery of new genes and variants that
help to unravel the pathogenic mechanisms driving
neuropathogenesis. One such discovery includes TRIO,
a gene recently implicated in neurodevelopmental delay.
Trio is a Dbl family guanine nucleotide exchange factor
(GEF) and a major regulator of neuronal development,
controlling actin cytoskeleton dynamics by activating the
GTPase Rac1.
Methods Whole-exome sequencing was undertaken on
a family presenting with global developmental delay,
microcephaly and mild dysmorphism. Father/daughter
exome analysis was performed, followed by conﬁrmatory
Sanger sequencing and segregation analysis on four
individuals. Three further patients were recruited through
the deciphering developmental disorders (DDD) study.
Functional studies were undertaken using patient-speciﬁc
Trio protein mutations.
Results We identiﬁed a frameshift deletion in TRIO that
segregated autosomal dominantly. By scrutinising data
from DDD, we further identiﬁed three unrelated children
with a similar phenotype who harboured de novo
missense mutations in TRIO. Biochemical studies
demonstrated that in three out of four families, the Trio
mutations led to a markedly reduced Rac1 activation.
Conclusions We describe an inherited global
developmental delay phenotype associated with a
frameshift deletion in TRIO. Additionally, we identify
pathogenic de novo missense mutations in TRIO
associated with the same consistent phenotype,
intellectual disability, microcephaly and dysmorphism
with striking digital features. We further functionally
validate the importance of the GEF domain in Trio
protein function. Our study demonstrates how genomic
technologies are yet again proving proliﬁc in diagnosing
and advancing the understanding of neurodevelopmental
disorders.
INTRODUCTION
Neurodevelopmental delay is genetically heterogen-
ous and affects between 1% and 3% of the general
population.1 The usage of next-generation genomic
techniques such as whole-exome sequencing (WES)
has facilitated the identiﬁcation of numerous novel
pathogenic variants implicated in the evolution of
neurodevelopmental pathology.2 One such gene on
chromosome 5, TRIO, has recently been identiﬁed
as a candidate for human neurodevelopmental
delay.3
Neurodevelopment is a complex process requir-
ing coordinated axonal guidance and neuronal
migration to facilitate the delivery of neurons from
the neuroepithelium to their synaptic target. This
process is driven by speciﬁc molecular cues, which
regulate the neuronal growth cone, residing at the
tip of the axon.4 Motility of the growth cone is, in
part, regulated through remodelling of the actin
cytoskeleton.5 6
Members of the Rho GTPase family are key
modulators of cytoskeletal dynamics.7 They play an
essential role in neurodevelopment through the
control of actin cytoskeleton dynamics, including
motility of the growth cone.8 Rho GTPases are acti-
vated by guanine nucleotide exchange factors
(GEFs). TRIO encodes a GEF expressed in many
tissues, including the central nervous system
(CNS).9 10 It is highly expressed in many areas of
the developing brain including the cerebellum,
cortex, hippocampi and thalami.10 11 Interestingly,
TRIO can be alternatively spliced, and, as a result,
can encode several isoforms whose expression is
nervous-system speciﬁc.11 12 Trio is thought to be
one of the major regulators of neuronal develop-
ment by controlling actin cytoskeleton remodelling
through the activation of the GTPase Rac1.13 The
importance of the Trio protein in neuronal devel-
opment is further emphasised by the fact that total
knockout or speciﬁc deletion of Trio in the mouse
nervous system is embryonically lethal; embryos
display defects in brain organisation and reduced
brain size.9 14 Deletion of Trio, speciﬁcally in the
hippocampus and in the cortex during early
embryogenesis, results in aberrant organisation of
these structures, impairing the learning ability of
these mice.10
Our ﬁndings consolidate and extend the human
phenotype recently reported by Ba et al.3 Through
the application of parent/offspring WES analysis,
we report three children from across the UK with
microcephaly and neurodevelopmental delay who
harbour de novo missense mutations in TRIO. We
also report a family with TRIO mutations that seg-
regate autosomal dominantly. We show for the ﬁrst
time that TRIO mutations identiﬁed in patients
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affect Trio function and consequently could be responsible for
the phenotype observed.
METHODS
Patients 1, 2 and 3 were assessed at the Wessex Clinical Genetics
Service (ﬁgure 1). Exome sequencing of patients 2 and 3 was
performed on DNA extracted from whole blood. Sequencing
and analysis were undertaken as previously described;15 all
variant positions reported are deﬁned on GRCh37 (hg19) and
TRIO transcript NM_007118. To validate the sample proven-
ance, a parallel SNP panel was applied to conﬁrm data
identity.16
Patients 4, 5 and 6 were referred to regional Clinical Genetics
services across the UK, where they were recruited to the deci-
phering developmental disorders (DDD) study (http://www.
ddduk.org). DDD has so far investigated over 4000 children
with severe, undiagnosed developmental delay, and their
parents, using a combination of genome-wide assays to detect
all major classes of genetic variation in the protein-coding
portion of the genome. Clinical information and phenotypes
have been recorded using the Human Phenotype Ontology via a
secure web portal within the DECIPHER database.17 18 DNA
samples from patients and their parents were analysed by the
Wellcome Trust Sanger Institute using high-resolution micro-
array analysis (array-comparative genomic hybridisation and
SNP genotyping) to investigate CNVs in the affected child,
and exome sequencing to investigate single-nucleotide variants
and small insertions/deletions (indels). Putative de novo
sequence variants were validated using targeted Sanger sequen-
cing. The population prevalence (minor allele frequency) of
each variant in nearly 15 000 samples from diverse populations
was recorded, and the effect of each genomic variant was pre-
dicted using the Ensembl Variant Effect Predictor.19 Likely
diagnostic variants in known developmental disorder genes
were fed back to the referring clinical geneticists for external
Sanger validation and discussion with the family via the patient’s
record in DECIPHER, where they can be viewed in an inter-
active genome browser. Full genomic datasets were also depos-
ited in the European Genome–Phenome Archive (http://www.
ebi.ac.uk/ega).
Functional analysis to assess input of variants was undertaken.
TRIO point mutants were generated by introducing a point
mutant in the wild-type (wt) form of green ﬂuorescent protein
(GFP)-tagged Trio using the Quick change site-directed muta-
genesis kit (Stratagene). The Rac1-guanosine triphosphate
(GTP) pull-down assay was performed using the Cdc42/Rac1-
interactive binding (CRIB) domain of PAK1 as described.20
Total HEK293T lysates and corresponding pull-downs retained
on GST-Sepharose beads were processed for western blotting
using the Rac1 (BD) and GFP (Clinisciences) antibodies.
RESULTS
Patients 1, 2 and 3
Patient 1 (see ﬁgure 1) was whole exome sequenced and a het-
erozygous frameshift deletion (p.Gln1489Argfs*11) in TRIO
was identiﬁed, which was paternally inherited. This variant is
predicted to cause nonsense-mediated decay of the transcript,
and thus prevent expression of this allele (table 1).21 She was
last assessed at the age of 17 months and was displaying signs of
mild developmental delay; she sat unsupported at 9 months and
walked unaided at 17 months. First words were spoken at
17 months and there was evidence of mild delay in expression
and comprehension. She is a fussy eater and has dietetic input
to increase caloriﬁc intake. There were some subtle behavioural
signs including poor attention. She is microcephalic with a head
circumference 5 SDs below the mean (ﬁgure 2). Dysmorphic
features included a short nose, long philtrum, thin upper lip,
epicanthic folds, 2/3 toe syndactyly and an almost absent ﬁfth
toe nail. She has right radial aplasia, a rudimentary thumb and
absent ﬁrst metacarpal. She was found to have multiple cardiac
septal defects at birth; at the age of 3 she has two small apical
muscular ventricular septal defects and a patent foramen ovale,
none of which are of concern clinically. The pregnancy was
complicated by pre-existing maternal type 2 diabetes mellitus,
which required insulin therapy. She also has a 381 kb 15q11.2
microdeletion.
Patient 2 is the father of patient 1 and was genotyped using
traditional Sanger methods. He harbours the same deletion in
TRIO in addition to the same 15q11.2 microdeletion. He dis-
played mild learning difﬁculties in childhood and attended a
specialist school. He is microcephalic with an occipital frontal
circumference (OFC) 3 SDs below the mean. Other dysmorphic
features include a straight nose, small jaw, pointed features,
low anterior hairline, ﬂattened thenar eminence, tapering digits,
ﬁfth ﬁnger clinodactyly and dental delay including absence or
failed eruption of the lower central incisors and all four lateral
molars.
Patient 3 is the uncle of patient 1 and brother of patient 2,
who underwent WES. He harbours the same deletion in TRIO
in addition to a pathogenic variant in KCNJ2 and the 15q11.2
microdeletion. He has learning difﬁculties and is microcephalic
with a head circumference 5 SDs below the mean. He has
similar dysmorphic features to his brother including a straight
nose, small jaw, low anterior hairline, pointed features and
short and tapering ﬁngers. He has a structurally normal heart
but experiences ventricular ectopic beats, which may be attri-
butable to his coexisting variant in KCNJ2.22 Similar to his
Figure 1 Pedigree of individuals 1, 2 and 3 (III1, II1 and II3,
respectively) obtained through the Wessex Clinical Genetics Service.
Affected individuals are shaded in black. Individuals who underwent
whole-exome sequencing are labelled with a “+”. Genotypic
information conﬁrmed by Sanger sequencing is displayed where known.
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Table 1 Clinical phenotypes
Phenotype Patient 1 (proband) Patient 2 (father) Patient 3 (paternal uncle) Patient 4 Patient 5 Patient 6
Background TRIO Mutation
Coding change
Protein change
Exon
Domain affected
Frameshift
c.4466delA
pGln1489Argfs*11
Exon 30
DH1
Frameshift
c.4466delA
pGln1489Argfs*11
Exon 30
DH1
Frameshift
c.4466delA
pGln1489Argfs*11
Exon 30
DH1
Missense
c.4283 G>A
p.Arg1428Gln
Exon 28
DH1
Missense
c.4381 C>A
p.Pro1461Thr
Exon 29
DH1
Missense
c.3239 A>T
p.Asn1080Ile
Exon 19
Spectrin repeat
MAF Novel Novel Novel Novel Novel Novel
Inheritance Inherited Inherited Inherited AD de novo AD de novo AD de novo
Sex F M M F F F
Gestational age (weeks) 38 − − 41 38 40
Development Age at last assessment 17 months 36 years 10 years 16 years 8 years 9 years
Early
milestones
First Smile NR NR NR 8 weeks 36 weeks NR
Sitting unsupported 9 months NR NR 10 months 11 months 11 months
Walking unaided 17 months NR NR 22 months 2.5–3 years 4–5 years
First words 17 months NR NR Unknown 4–5 years Unknown
Current
developmental
level
General Mild developmental delay Mild learning difficulties attended
special school
Mild developmental delay Global developmental delay Global
developmental delay
Global developmental
delay
Language Mild delay in expression and
comprehension
Learning difficulties Unable to read or write but
very talkative
Non-verbal (Makaton)
Growth Height 70 cm (<0.4th) 167 cm (9th) 126 cm (2nd) 159.4 cm (25th) 121.2 cm (9th) 121.6 cm (2nd)
Weight 7.9 kg (<0.4th) 69.9 kg (50th–75th) 20.5 kg (<0.4th) 41.1 kg (0.4th) 21.2 kg (9th) 20.2 kg (2nd)
Occipital frontal
circumference
42 cm (-5sd) 52 cm (-3sd) 48 cm (-5sd) 48 cm (-5sd) 47 cm (-5sd) 54.3 cm (75th)
Neurological Stereotypies
Aggression
Poor attention
Other
−
−
+
−
NR NR +
+
−
Obsessive compulsive traits
−
−
+ ADHD
disrupted sleep
+
+
−
−
Other − − − Pain insensitivity, urinary
incontinence
− Seizures (nocturnal
tonic–clonic), gait ataxia
Gastrointestinal Infantile feeding
difficulties
+ NR NR − + +
Other Dietician input Constipation Previous gastrostomy
Skeletal Digits Short tapering fingers with swelling
of PIP joints fifth finger
cleinodactyly
Short tapering fingers with swelling of
PIP joints and shortening of the
metacarpals and phalanges
Short tapering fingers with swelling of PIP
joints, fifth finger cleinodactyly, 2/3
left-sided toe syndactyly
Short tapering fingers with
swelling of PIP joints, fifth
finger cleinodactyly, 2/3
left-sided toe syndactyly
2/3 toe syndactyly
and almost absent
fifth toe nail
−
Spine Rotational scoliosis, right radial
aplasia and rudimentary thumb and
absent metacarpal, no radial
synostosis
Minor bony abnormalities of the low
dorsal vertebrae with rotational scoliosis
of the thoracolumbar spine
− −- − Thoracolumbar scoliosis
Additional Facial Short nose, long philtrum, thin
upper lip, epicanthic folds,
synophrys
Straight nose, small jaw, pointed
features, low anterior hairline,
asymmetry
Straight nose, small jaw, low anterior
hairline with frontal upsweep of hair,
pointed features, asymmetry
Congenital ptosis, upslanting
palpebral fissures, large
fleshy ears, synophrys
Flat nasal bridge,
synophrys
Plagiocephaly,
Angelman-like facies,
asymmetry
Dental NR Dental delay Dental delay Dental overcrowding NR NR
Other 2 VSDs and PFO, maternal Type 2
DM
NR Asymptomatic ventricular
ectopic beats with RBBB
Good musical memory Strabismus,
perforated ear drum
NR
Additional variants 15q11.2 microdeletion 15q11.2 microdeletion KCNJ2 (p.T75M) 15q11.2 microdeletion − − −
−, absent; +, present; AD, autosomal dominant; ADHD, attention-deficit hyperactivity disorder; DM, diabetes mellitus; F, female; M, male; NR, not recorded; PFO, patent foramen ovale; PIP, proximal interphalangeal; RBBB, right bundle branch block; VSD,
ventricle septal defect.
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brother, he too has dental abnormalities with absence of any
upper or lower lateral incisors. This family has been previously
reported.23
Patient 4
Patient 4 has a de novo missense mutation in TRIO (p.
Arg1428Gln). She was last assessed at the age of 16 years when
she had evident global developmental delay. From a gross motor
perspective, she sat unsupported at 10 months and walked at
22 months. It was not possible to elucidate the age of her ﬁrst
words; however, at the age of 16 years, although talkative, she
remains unable to read or write. No feeding difﬁculties have
been reported. This individual has numerous behavioural difﬁ-
culties including stereotypies and obsessive compulsive traits.
There was previous concern about aggressive and disruptive
behaviour, which has now resolved. She is microcephalic with
an OFC 5.41 SDs below the mean. Some dysmorphism was
noted including congenital ptosis, upslanting palpebral ﬁssures,
large ﬂeshy ears and ﬁfth ﬁnger clinodactyly. Neurological fea-
tures include insensitivity to pain and urinary incontinence.
Patient 5
Patient 5 was last assessed at the age of 8 years. She has a de
novo missense mutation in TRIO (p.Pro1461Thr). She has
global developmental delay and is microcephalic with an OFC 5
SDs below the mean. She sat unsupported at 11 months and
walked unaided at 2½–3 years. Her ﬁrst words were spoken
between 4 and 5 years. Early feeding difﬁculties were reported
including a poor suck, impaired bottle feeding and failure to
thrive. Behavioural features include attention-deﬁcit hyperactiv-
ity disorder and poor sleep.
Patient 6
Patient 6 has a de novo missense mutation in TRIO (p.
Asn1080Ile) and she was last assessed at the age of 9 years. She
has global developmental delay, most notably affecting gross
motor and language development. She sat unsupported at
11 months and walked unaided at 4–5 years. She has no verbal
communication and uses Makaton. She is still in nappies. There
were some early feeding difﬁculties requiring gastrostomy; these
have now resolved, although she remains with a thin body
habitus. She has behavioural features that include hand stereoty-
pies and aggressive episodes; she bites herself and can attack her
younger brother. Head circumference is within the normal
range. She has facial features that resemble Angelman-like facies
with plagiocephaly. Neurological features include nocturnal
tonic–clonic seizures, and a wide-based and ataxic gait.
TRIO mutations
The six patients presented in this study have mutations in TRIO,
a gene containing 57 exons that encodes a member of the Dbl
family of GEFs, displaying strong conservation across evolu-
tion.13 Alternative splicing of TRIO results in isoforms that
harbour either one or both of the highly conserved Dbl hom-
ology–Pleckstrin homology (DH–PH) domains. Out of the six
Trio isoforms, ﬁve contain the ﬁrst DH–PH domain, which spe-
ciﬁcally catalyses exchange of GDP for GTP on RhoG and
Rac1.
Figure 2 Clinical photographs. Photographs of individuals 1–6, taken at ages 3; 25; 22; 18; 2 and 11; 18 months, 7 and 10, respectively. All
individuals harbour TRIO mutations. Individual 1 is the daughter of individual 2. Individuals 2 and 3 are brothers and have been previously
described.32 Individuals 4, 5 and 6 are unrelated. Common features among studied individuals include microcephaly (seen in patients 1–5), mild
dysmorphic facies, tapering ﬁngers with prominent proximal interphalangeal joints, ﬁfth ﬁnger clinodactyly and 2/3 toe syndactyly.
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We set out to test whether the mutations identiﬁed in Trio
could impact on its function and consequently contribute to
the phenotypes observed in the six patients. The RhoGEF Trio
is a major regulator of neuronal development, mainly through
its activation of Rac1. Patients 1, 2 and 3 share a frameshift
mutation (p.Q1489fs*) resulting in a truncated Trio protein
(ﬁgure 3); it would be expected that this truncated transcript
would be degraded by nonsense-mediated decay, resulting in the
production of negligible protein product. Patients 4, 5 and 6
harbour de novo missense mutations. Interestingly, among the
four mutations identiﬁed, three lie within the GEFD1 domain,
responsible for Rac1 activation (p.R1428Q, p.P1461T and p.
Q1489fs*) (ﬁgure 3C). Furthermore, the mutations affect highly
conserved residues, since both R1428 and P1461 are present in
Trio from invertebrates to mammals (ﬁgure 4B). They lie,
respectively, within the α-5 and α-6 helices of the DH domain,
which have been shown to interact with the target GTPase and
occur at the protein–protein interface (ﬁgure 4A).24–26 The
truncated mutant of Trio, p.Q1489fs*, is missing the PH1
domain, which is shown to be required for efﬁcient GDP/GTP
exchange.27 In contrast to the other ﬁve patients, individual 6
has a missense mutation (p.N1080I) within a spectrin repeat
(ﬁgure 3C).
We tested whether the mutations identiﬁed in our six patients
affected Trio-mediated Rac1 activation (ﬁgure 3D,E). We intro-
duced four mutations individually into the Trio cDNA and
expressed wt or mutant GFP-tagged Trio proteins in HEK293T
cells. Rac1-GTP pull-down experiments were performed using
the CRIB domain of PAK1. As expected, Rac1-GTP was efﬁ-
ciently pulled down from cells expressing wt Trio. In contrast,
the pull-down of active Rac1 from cells expressing the Trio
p.R1428Q, p.P1461T or the truncated mutant p.Q1489fs* was
strongly reduced, although to a lesser extent than the fully dead
GEF mutant used as a negative control (Q1427A/L1435E).28
The results obtained with the two point mutants in the GEFD1
domain are therefore consistent with a crucial function of these
two residues in Rac1 activation. The p.N1080I mutant (in indi-
vidual 6) did not affect Trio-mediated Rac1 activation. Taken
together, our results reveal that in ﬁve out of six patients har-
bouring a mutation in the TRIO gene, Rac1 activation is
Figure 3 TRIO and its functional domains. (A) Genomic location of TRIO on the short arm of chromosome 5p15.2. (B) Graphical representation of
the TRIO gene, comprising its 57 exons (vertical lines) spanning 366.5 kb. Exons are numbered alongside their relative position to coding domains.
(C) Schematic overview of the Trio protein and its domains alongside the four mutations identiﬁed in the six patients from this study. Trio displays
three enzymatic domains. Each guanine nucleotide exchange factor (GEF) module contains a catalytic domain, called Dbl homology (DH) domain
(in reference to Dbl, the ﬁrst RhoGEF identiﬁed as an oncogene in mammalian cells), and a Pleckstrin homology (PH) domain that plays a role in
GEF activation and localisation. The ﬁrst GEF domain, GEFD1, activates Rac1 and RhoG. The second GEF domain, GEFD2, acts on RhoA. In addition,
Trio harbours numerous accessory domains. Listed from the N-terminus to the C-terminus, these include a CRAL-Trio/Sec14 motif; several
spectrin-like repeats; two Src-homology 3 (SH3) motifs; and an immunoglobulin (Ig)-like domain. (D) Rac1-GTP pull-down assay. HEK293T cells
(transfected as indicated) were lysed and active GTP-Rac1 was afﬁnity puriﬁed using the Cdc42/Rac1-interactive binding (CRIB) domain of PAK1,
immobilised on Glutathione-Sepharose beads. Puriﬁed GTP-bound and total Rac1 were detected by western blot, using an anti-Rac1 antibody.
Protein expression in the cell lysates was veriﬁed by immunoblotting with an anti-green ﬂuorescent protein (GFP) antibody. One representative
experiment is shown. (E) Quantiﬁcation of the Rac1-GTP pull-down assay shown in (D). Rac1 activation mediated by wt Trio was arbitrarily set to
100%, in order to be able to compare the individual experiments. The % of Rac activation was calculated from at least six independent experiments
(mean ±SEM). *p< 0.015, ***p< 0.0001. Of note, all three mutations lying in the DH1 domain strongly affect Trio-mediated Rac1 activation.
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strongly reduced, demonstrating that Trio function is affected in
these patients.
DISCUSSION
TRIO is highly expressed in the developing brain; rat models
show transcripts present in all major brain areas postnatally.11 29
TRIO and its paralog kalirin play a fundamental role in mamma-
lian neuronal development. Trio deletion in mice results in
impaired neuronal migration and axon guidance defects, global
brain reduction and aberrant structural development of the
hippocampus, cerebellum and cortex.9 14 Complete knockout
mice are embryonically lethal; they have smaller brains and
aberrant organisation in the hippocampus and hindbrain.9 10 14
A mouse model recently reported with a Trio knockout speciﬁc
to the hippocampus and brain cortex addressed the role of Trio
in postnatal brain development, concluding that Trio regulates
the neuronal development of the hippocampus and affects the
learning ability and intelligence of adult mice.10
Five of the six patients we report share a core phenotype
comprising intellectual disability (ID), behavioural difﬁculties,
subtle dysmorphism and microcephaly. This presentation aligns
with the phenotype recently presented by Ba et al,3 who
screened 2300 ID cases and identiﬁed four truncating mutations
in TRIO. Similarly, they described skeletal anomalies, short
stature, feeding difﬁculties and facial asymmetry. Perhaps most
striking, however, are the similarities of the digital dysmorphol-
ogy, most notably phalangeal hypoplasia, swollen proximal
interphalangeal (PIP) joints and tapering ﬁngers shared between
their study and our ﬁndings. The microcephalic presentation is
likely to be primary in nature, in which the skull is small
because the underlying brain is small. Noteworthy, the micro-
cephaly we describe is more severe than in the individuals
reported by Ba et al,3 who all harboured loss-of-function muta-
tions. Of interest, we showed that microcephaly was only
present in individuals who harboured mutations in the GEFD1
domain affecting Rac1 activation by Trio. Since Trio function in
the nervous system is mainly mediated by Rac1 activation, we
can propose from these data that alteration of Rac1 activation
by Trio variants is associated with microcephaly. Furthermore,
we have recently shown that Trio is implicated in cell division
Figure 4 The structure of Trio. (A)
Quaternary structure of the Dbl
homology (DH) domain of Trio (teal) in
complex with the small GTPase
substrate (yellow). Mutations within
the DH seen in patients 4 and 5 are
indicated in red; both mutations can
be seen to occur at the protein–
substrate interface. PDB IDs: DH
domain—1NTY; GTPase substrate—
1KZ7.33 34 Figure generated using
PyMOL.35 (B) Sequence alignment of
the DH1 domain of Trio (and Kalirin)
across evolution. Sequences were
obtained from NCBI databases and
aligned with Clustal Omega. Identical
residues are labelled in red, similar
residues in blue. The structural features
of the protein domain (α-helices) are
depicted schematically and labelled on
top of the sequence. The positions of
the mutations p.R1428Q and p.P1461T
are indicated in bold and boxed in red.
Note that p.R1428Q and p.P1461T
each affect a highly conserved residue
within a very conserved region of the
DH domain, in helices α-5 and α-6.
Helices α-1, α-3b, α-5 and α-6 make
contact with the target GTPase.
Represented species are Homo sapiens
(h), Mus musculus (m), Rattus
norvegicus (r), Xenopus laevis (x),
Danio rerio (z), Drosophila
melanogaster (d), Caenorhabditis
elegans (c).
6 Pengelly RJ, et al. J Med Genet 2016;0:1–8. doi:10.1136/jmedgenet-2016-103942
Cognitive and behavioural genetics
group.bmj.com on August 8, 2016 - Published by http://jmg.bmj.com/Downloaded from 
by counteracting the effect of MgcRacGAP on Rac1 during
cytokinesis.30 Interestingly, many genes associated with cell-cycle
regulation have been found to be mutated in different forms of
microcephaly.31 32 Therefore, the microcephaly phenotype
observed in patients with TRIO mutations could also originate
from a cell-cycle defect.
In contrast to patients 1–5, one individual in our study (indi-
vidual 6) is somewhat of a phenotypic outlier; although she has
ID, behavioural difﬁculties and dysmorphism, she is the only
patient we report without microcephaly and who has seizures,
complete speech failure and plagiocephaly. Unlike individuals
1–5 who have mutations affecting the DH1–PH1 domain, indi-
vidual 6 has a missense mutation that affects a spectrin repeat
and was functionally shown not to affect Trio-mediated Rac1
activation (ﬁgure 3). Spectrin repeats are important for Trio
function as they bind many Trio regulators, such as NAV1,
DISC1 and KidIns220.13 33 Therefore, we can hypothesise that
the mutant Trio, p.N1080I, is mediated by a pathway independ-
ent of Rac1 activation, and could impair the binding of Trio to
its interactors, potentially leading to protein mislocalisation.
TRIO is expressed in many tissue types; however, its role
outside of the CNS remains to be fully elucidated. In addition,
interpretation of a truly speciﬁc TRIO phenotype is confounded
by additional ﬁndings; notably a 15q11.2 microdeletion in
patients 1 and 2 and a pathogenic KCNJ2 variant in patient
3. Mutations in KCNJ2 have been associated with Anderson–
Tawil syndrome, short QT and familial atrial ﬁbrillation,22 34
likely explaining the ventricular ectopic beats seen in individual
3. It is also of note that individual 1 has right radial aplasia and
ventricular septal defects, which may be secondary to an in
utero environment complicated by maternal type 2 diabetes.35
Two of our probands displayed additional neurological signs
including seizures, ataxia and pain insensitivity, and three of the
probands had feeding difﬁculties. Furthermore, the ID reported
was variable. The phenotypic variability could be related to the
differing variant types (loss of function vs missense) and the
importance of mutations affecting different exon positions
within the DH1–PH1 domain and their consequent effect on
protein function. Of particular interest, there was little differ-
ence in phenotypic severity between individuals harbouring
loss-of-function mutations versus missense mutations that did
not signiﬁcantly alter protein length, and nor in the biological
disruption of Trio-mediated Rac1 activity.
CONCLUSIONS
We are the ﬁrst study to describe pathogenic missense mutations
in TRIO and a TRIO syndrome that segregates in an autosomal-
dominant pattern. Our ﬁndings corroborate and extrapolate pre-
vious literature; we show that mutations in TRIO affecting the
RhoGEF1 domain cause a phenotype comprising microcephaly,
ID, behavioural difﬁculties and dysmorphism with speciﬁc
digital features. We functionally prove that genotypic, patient-
speciﬁc TRIO mutants cause protein dysfunction modulated
through reduced Rac1 activity, and that microcephaly was only
present in individuals who harboured mutations in the GEFD1
domain. It now remains to be established whether the pheno-
typic contribution of TRIO variants in patients are attributable
to the function of Trio in cell division and/or neuronal
differentiation.
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